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Abstract: In an effort to study curcumin analogues as an alternative to improve the therapeutic 
efficacy of curcumin, we screened the cytotoxic potential of four diarylpentanoids using 
the HeLa and CaSki cervical cancer cell lines. Determination of their EC50 values indicated 
relatively higher potency of 1,5-bis(2-hydroxyphenyl)-1,4-pentadiene-3-one (MS17,  
1.03 ± 0.5 μM; 2.6 ± 0.9 μM) and 1,5-bis(4-hydroxy-3-methoxyphenyl)-1,4-pentadiene-3-one 
(MS13, 2.8 ± 0.4; 6.7 ± 2.4 μM) in CaSki and HeLa, respectively, with significantly 
greater growth inhibition at 48 and 72 h of treatment compared to the other analogues  
or curcumin. Based on cytotoxic and anti-proliferative activity, MS17 was selected for 
comprehensive apoptotic studies. At 24 h of treatment, fluorescence microscopy detected that 
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MS17-exposed cells exhibited significant morphological changes consistent with apoptosis, 
corroborated by an increase in nucleosomal enrichment due to DNA fragmentation in 
HeLa and CaSki cells and activation of caspase-3 activity in CaSki cells. Quantitative  
real-time PCR also detected significant down-regulation of HPV18- and HPV16-associated 
E6 and E7 oncogene expression following treatment. The overall data suggests that MS17 
treatment has cytotoxic, anti-proliferative and apoptosis-inducing potential in HPV-positive 
cervical cancer cells. Furthermore, its role in down-regulation of HPV-associated oncogenes 
responsible for cancer progression merits further investigation into its chemotherapeutic 
role for cervical cancer. 
Keywords: curcumin analogue; diarylpentanoid; cervical cancer; cytotoxicity; apoptosis; 
oncogene; E6; E7; HeLa cells; CaSki cells 
 
1. Introduction 
Cervical cancer currently ranks as the second most common female cancer in the world affecting 
women between the ages of 15 to 44 years of age [1,2] and is responsible for the second highest cause 
for female cancer mortality worldwide [2]. Cervical cancer is attributed to specific human papillomavirus 
infections, with at least 71% of invasive cervical cancer caused by HPV high risk types 16 and 18 [3]. 
Upon infection, the circular viral genome often becomes integrated into the host genome and can 
selectively up-regulate the expression of viral oncogenes, E6 and E7, giving these cells a selective 
growth advantage over cells that harbour the viral genome as a nuclear plasmid [4]. These two 
oncogenes are responsible for the continued immortalized state of the cervical cells. 
Curcumin has been identified as the active component derived from the rhizomes of the turmeric 
plant (Curcuma longa), a perennial herb used for its yellow colour and flavour in cooking. Chemically 
known as diferuloylmethane (bis-α,β-unsaturated β-diketone), curcumin has been shown to have a 
wide variety of therapeutic effects, ranging from anti-inflammatory, antioxidative, chemopreventive 
and anti-metastatic [5–8]. Besides its anti-metastatic and anti-proliferative effects on cancer cell 
growth [9], research on the signalling pathways that curcumin treatment targets, shows that it potently 
acts on major intracellular components involved in cancer. Curcumin affects critical genes such as  
NF-κβ, STAT, cyclins, MMPs, VEGF and caspases which are involved in key processes such as 
inflammation, genomic modulations, cell invasion and cell death pathways as reviewed by [7–9]. 
Specific reports have also discussed the role of curcumin in its antitumor activity in cervical cancer. 
Curcumin has shown selective cytotoxicity for HPV16- and HPV18-infected cells and induces 
apoptosis in cervical cancer cells by causing nuclear fragmentation, down-regulation of NF-κβ [10] 
and causes downregulation of E6 and E7 oncogenes and tissue specific gene expression of HPV [10–12]. 
While animal studies and clinical trials indicate that curcumin has a good safety index [13–18], the 
poor bioavailability of curcumin [19–22] has been highlighted as a critical issue to resolve before it 
can be considered as an effective therapeutic agent. Research conducted to overcome the problems 
with the bioavailability of curcumin includes the development of curcumin formulated with  
adjuvants, encapsulated by nanoparticles and liposomes or complexed with micelles and phospholipid 
Molecules 2015, 20 11832 
 
 
complexes [7,23]. Recently studies have also reported success in combinatorial strategies coupling 
curcumin with other treatments that show synergistic effects in sensitizing resistant cells to drugs 
(reviewed in [24]) and suppressing cell growth by inducing apoptosis [25] and causing cell cycle  
arrest [26]. 
In addition to these studies, the use of synthetic curcumin analogues is also being studied as an 
option to overcome the limitations of curcumin while retaining its safety and efficacy. Structural 
modification studies elucidated that while specific substitutions at the aromatic rings [27,28] and 
heterocyclic linkers [28] enhanced the efficacy of the analogue, the 3-oxo-1, 4-pentadiene analogue was 
a basis for cytotoxic induction. Studies have reported that diarylpentanoids, a group of curcumin type 
compounds with a 5-carbon linker between its aryl rings, displayed greater growth inhibitory activity 
than curcumin and other 7-carbon curcuminoids [27]. 
The evidence for the anticancer therapeutic potential of diarylpentanoids is found in the results of 
numerous studies that show that diarylpentanoids induce growth suppressive effects in a wide range of 
cancer cell lines [29–40]. It is clear that diarylpentanoids have potential anticancer properties and to 
our knowledge, the study concerning the anti-carcinogenic potential of diarylpentanoids in cervical 
cancer is limited and merits further investigation. 
Hence, it would be crucial to determine whether diarylpentanoids displayed anticancer activity by 
assessing its cytotoxicity, anti-proliferative activity and apoptosis-inducing potential when treated on 
cervical cancer cells, specifically HeLa and CaSki. Both cell lines are commonly used in in vitro 
cervical cancer research, and contain the high risk HPV types 18 and 16 viral genomes respectively. 
As seven out of ten cases of invasive cervical cancers are due to infection by these high risk subtypes, 
the use of these cell lines in the study is particularly relevant [2]. Furthermore, as HPV oncogenes play 
a crucial role in the progression of cervical cancer, the investigation was extended to include the study 
of the prospective role of the selected diarylpentanoid in inhibiting the expression of E6 and E7 
oncogenes in HPV16 and HPV18-infected cervical cancer cells. 
The aim of this study was to determine the cytotoxic, anti-proliferative and apoptotic activity of 
selected diarylpentanoid treatment on HPV-infected human cervical cancer cells as well as to study its 
effects on HPV-associated oncogene expression. Preliminary screening of 29 synthetic symmetrical 
diarylpentanoids was used to determine the potential cytotoxicity of these compounds on HeLa and 
CaSki cell growth. The selection process for candidate diarylpentanoids for in-depth studies prioritized 
compounds that dissolved well in dimethylsulfoxide (DMSO), were not strongly coloured (so as not to 
confound results from the colorimetric assay) and exhibited dose-dependent growth inhibitory effects 
compared to its untreated control. Based on these criteria, four compounds, 1,5-bis(4-hydroxy-3-
methoxyphenyl)-1,4-pentadiene-3-one (MS13), 1,5-bis(2-hydroxyphenyl)-1,4-pentadiene-3-one (MS17), 
1,5-bis(3-fluorophenyl)-1,4-pentadiene-3-one (MS40E) and 2,6-bis(3-fluorobenzylidene)cyclohexanone 
(MS49) were selected for further investigation. These four analogues were previously shown to display 
significant anti-proliferative activity and apoptotic properties when treated on androgen-independent 
human prostate cancer cells [41]. Its effects on HPV-infected human cervical cancer cells, however, 
are currently unknown. 
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2. Results and Discussion 
2.1. Screening and Cytotoxicity of Diarylpentanoids 
2.1.1. Diarylpentanoids Induce Cytotoxic Effects on HeLa and CaSki Cell Growth 
Between treated and non-treated HeLa cells (Figure 1), MS17 showed the most significant 
inhibition of cell growth with cell viability decreasing to 36% from a dose as low as 3.1 μM and 
gradually decreasing to 14% at 6.3 μM and then to less than 10% cell viability from 12.5 to 100 μM. 
MS13 follows closely in cytotoxicity with cell viability decreasing to approximately 12% beginning 
from 12.5 μM and decreasing to below 10% beyond this dose. MS49 and MS40E show significant 
growth inhibition of approximately 75% beginning at 12.5 and 25 μM respectively. MS17 showed 
more potent effects in CaSki (Figure 2) compared to HeLa cells, with significant reduction in cell 
viability beginning from 1.6 μM (30%) followed by 90% reduction in CaSki cell viability from 3.1 to 
100 μM. MS13 followed a similar trend by exhibiting a significant decrease in cell growth beginning 
from 3.1 μM (50%); dosing beyond 6.3–100 μM displayed around 10% cell growth after treatment. 
MS40E showed significant growth inhibition from 6.3 μM (80%) to100 μM (90%) but MS49  
only showed a similar effect from 12.5 μM (20% cell viability) and 25–100 μM (~10% cell  
viability) onwards. 
Curcumin on the other hand only showed significant growth inhibition of 50% at 25 μM in CaSki;  
a similar effect was only observed beginning at 50 μM in HeLa cells. Cell viability data was used to 
assess the EC50 values for each compound (Table 1). MS17 had the highest inhibitory effect on CaSki 
and HeLa cervical cancer cell growth (CaSki EC50, 1.03 μM; HeLa EC50, 2.6 μM), followed by MS13 
(CaSki EC50, 2.8 μM; HeLa EC50, 6.7 μM), MS49 (CaSki EC50, 6.0 μM; HeLa EC50, 8.3 μM), MS40E 
(CaSki EC50, 3.5 μM; HeLa EC50, 15.5 μM) and curcumin (CaSki EC50, 15.8 μM; HeLa EC50,  
26.7 μM). 
Table 1. In vitro cytotoxicity (EC50, µM) of curcumin and diarylpentanoids against HeLa, 
CaSki and MRC9 cells and their selective indices. 
Compound 
EC50 (Mean ± S.E.M.) Selective Index 
HeLa CaSki MRC9 HeLa CaSki 
MS13 6.7 ± 2.4 2.8 ± 0.4 9.7 ± 2.4 145 346 
MS17 2.6 ± 0.9 1.03 ± 0.5 4.6 ± 1.2 177 447 
MS40E 15.5 ± 1.9 3.5 ± 0.4 31.7 ± 3.2 204 906 
MS49 8.3 ± 4.6 6.0 ± 2.9 16.4 ± 4.4 199 273 
Curcumin 26.7 ± 14.3 15.8 ± 3.1 26.6 ± 3.2 100 168 
Results are shown as mean ± standard deviation (S.D.) from three independent experiments. 
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Figure 1. The inhibitory effects of cell viability by curcumin, MS13, MS17, MS40E and 
MS49 in HeLa cancer cell line compared to untreated sample (CONT). Results are 
expressed as means of percentage cell viability and comparison between data sets 
performed using ANOVA. Experiments were performed in triplicates and results compared 
between three independent experiments. Asterisks indicate statistically significant (* for  
p < 0.05, *** for p < 0.001, **** for p < 0.0001) differences between the means of values 
obtained with treated vs. untreated cells. Error bars depict mean ± SEM. 
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Figure 2. The inhibitory effects of cell viability by curcumin, MS13, MS17, MS40E and 
MS49 in CaSki cancer cell line compared to untreated sample (CONT). Results are 
expressed as means of percentage cell viability and comparison between data sets 
performed using ANOVA. Experiments were performed in triplicates and results compared 
between three independent experiments. Asterisks indicate statistically significant (* for  
p < 0.05, ** for p < 0.01, **** for p < 0.0001) differences between the means of values 
obtained with treated vs. untreated cells. Error bars depict mean ± SEM. 
These results indicate that, on the whole, the four diarylpentanoids displayed comparably improved  
dose-dependent cell growth inhibition compared to curcumin. Furthermore, it was noted that the EC50 
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values calculated for MS17 were several fold lower in HeLa and CaSki cells compared to MS13, 
MS40E, MS49 and curcumin, indicating the relatively higher potency of MS17. Interestingly, MS17 
also showed a cell-line specific effect as it possessed a generally lower EC50 value in CaSki cells 
compared to HeLa. All diarylpentanoids and curcumin were observed to show a similar specificity for 
inducing greater cytotoxicity in CaSki compared to HeLa. 
Evaluation of diarylpentanoid toxicity on the non-cancerous lung fibroblast cell line, MRC9, noted 
that a much higher dose was required to cause MRC9 cell viability to decrease by 50% compared to 
the cervical cancer cell lines. The EC50 values of MS13, MS17, MS40E, MS49 and curcumin in 
MRC9 were determined as 9.7 ± 2.4, 4.6 ± 1.2, 31.7 ± 3.2, 16.4 ± 4.4 and 26.6 ± 3.2, respectively. As 
shown previously [42], the EC50 values were used to calculate the selective index, SX (Table 1), a 
baseline used to assess the selective toxicity of the diarylpentanoids towards cancerous cells over 
normal cells. Not only do MS13, MS17, MS40E and MS49 show SX values that exceed those of 
curcumin, it was noteworthy that the SX for all analogues in CaSki were several fold higher compared 
to HeLa. 
2.1.2. Diarylpentanoids Inhibit HeLa and CaSki Cell Proliferation 
While the cytotoxicity of diarylpentanoid treatment was determined to be dose-dependent, we were 
interested in investigating whether the compounds also displayed time-dependent effects on cell 
proliferation rate. Cell viability was measured after treatment with diarylpentanoids for 24, 48 and 72 h. 
The percentage cell viability of vehicle-treated (DMSO only) cells was measured to assess MTT 
turnover over time in the absence of diarylpentanoid treatment. It was observed that cell viability 
increased significantly between 24 and 72 h, indicating that cell proliferation increases as a function of 
time. This pattern is noticeably altered by drug treatment in a time-dependent manner. 
When treated with MS13 at 12.5 μM and above, HeLa cell viability (Figure 3) was significantly 
reduced by 72% at 24 h, and by approximately 91% and 95% at 48 and 72 h respectively. HeLa 
treatment with 6.3 μM onwards of MS17 also displayed a substantial decrease of cell viability to 34% 
when treated for 24 h, while treatment for 48 and 72 h at the same dosage range caused cell growth to 
reduce to 12% and 5%, respectively. In fact, statistical comparison of the overall anti-proliferative 
effects of MS13 and MS17 on HeLa cells indicate that they were significantly higher at 48 and 72 h 
compared to 24 h (p < 0.0001). Dosing onwards from 25 μM of MS40E and MS49 and 50 μM of 
curcumin caused significant reduction of cell growth below 50% at all three time points. 
In CaSki cells (Figure 4), treatment with 12.5 μM of MS13 led to a notable decline of cell viability 
of approximately 50% induced by 12.5 μM at 24 h after treatment and to 21% and 9% induced from 
6.3–100 μM at 48 and 72 h post-treatment. Doses from 12.5 μM onwards of MS17 was required to reduce 
cell growth to 43% at 24 h, but 48 and 72 h after treatment only required a concentration range of  
3.1–100 μM to reduce cell viability to 22% and 9% respectively. Similar to the effects of MS13 and 
MS17 in HeLa, comparison of the overall cell viability through time points suggested that there was a 
significant anti-proliferative activity that increased from 24 to 72 h (p < 0.0001). Treatment of CaSki 
cells with 12.5 μM onwards of MS40E and MS49 and from 25 μM curcumin onwards caused a 
significant decline in cell viability at 24, 48 and 72 h. 
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Overall, it was noted that treatment with the diarylpentanoids and curcumin had both time- and  
dose-dependent anti-proliferative activity on HeLa and CaSki cells. In most cases, treatment significantly 
caused higher growth inhibition at 48 and 72 h compared to 24 h. 
 
Figure 3. The anti-proliferative effects of MS13, MS17, MS40E and MS49 on HeLa 
cervical cancer cells at 24, 48 and 72 h. Results are expressed as means of percentage cell 
viability and comparison between data sets performed using ANOVA. Vehicle-treated 
controls were included to assess changes in untreated cell viability over time. Experiments 
were performed in triplicates and results compared between three independent 
experiments. Asterisks indicate statistically significant (* for p < 0.05, ** for p < 0.01,  
*** for p < 0.001, **** for p < 0.0001) differences between the means of values obtained 
with treated vs. untreated cells. Error bars depict mean ± SEM. 
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Figure 4. The anti-proliferative effects of MS13, MS17, MS40E and MS49 in CaSki 
cervical cancer cells at 24, 48 and 72 h. Results are expressed as means of percentage cell 
viability and comparison between data sets performed using ANOVA. Vehicle-treated 
controls were included to assess changes in untreated cell viability over time. Experiments 
were performed in triplicates and results compared between three independent 
experiments. Asterisks indicate statistically significant (** for p < 0.01, *** for p < 0.001, 
**** for p < 0.0001) differences between the means of values obtained with treated vs. 
untreated cells. Error bars depict mean ± SEM. 
Most notably, even though MS13 and MS17 showed the most potent cytotoxic effects compared to 
MS40E, MS49 and curcumin, MS17 caused significantly greater anti-proliferative effect compared to 
MS13 at 48 and 72 h after treatment. 
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2.2. Apoptotic Activity Induced by MS17 
2.2.1. Morphological Observation of Treated Cancer Cells Using Fluorescence Microscopy 
The induction of apoptosis on HeLa and CaSki cells by MS17 treatment was first evaluated by 
assessing classical morphological changes associated with apoptotic cell death by double staining with 
acridine orange (AO) and ethidium bromide (EB) followed by fluorescent microscopic analysis. 
AO is taken up by both viable and dead or dying cells and intercalates into double stranded DNA 
emitting green fluorescence while EB penetrates non-viable cells and emits red fluorescence. Hence, 
by using previously described features [43,44], it is possible to identify between viable cells, cells 
undergoing early/late apoptosis and necrotic cells. Live cells with intact membranes would stain a 
uniform green colour while live (early) apoptotic cells would exhibit a bright green-yellow due to the 
chromatin condensation that occurs in early apoptosis which may take the form of bright beads around 
the nucleus. Late apoptotic cells would also show similar features of chromatin condensation but due 
to increased permeability of EB, would emit a bright red (or yellow-orange) fluorescence. Necrotic 
cells would be fully permeable to AO and EB and stain uniformly orange. 
As the concentration of MS17 increased, the number of uniformly green viable cells (white arrows) 
decreased. When HeLa (Figure 5a) and CaSki (Figure 6a) cells were exposed to 3 and 2 µM 
respectively of MS17 for 24 h, there was a heterogeneous population of viable and early apoptotic 
cells (yellow arrows) characterised by bright green or green-yellow cells with chromatin condensation. 
 
(a) 
Figure 5. Cont. 
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(b) 
Figure 5. (a) Detection by fluorescent microscopy of acridine orange/ethidium bromide 
double-stained control and MS17-treated HeLa cervical cancer cells (24 h). Viable cells 
have uniform green nuclei with organised structure (white arrows) while early apoptotic 
cells would exhibit a bright green-yellow due to chromatin condensation that occurs in 
early apoptosis (yellow arrows). Late apoptotic cells (blue arrows) would also have  
bright-red (or yellow-orange) nuclei with condensed or fragmented chromatin and necrotic 
cells would stain uniformly orange (red arrows). Magnification 100×; (b) Detection by 
fluorescent microscopy of acridine orange/ethidium bromide double-stained control and 
MS17-treated HeLa cervical cancer cells (48 h). Viable cells have uniform green nuclei 
with organised structure (white arrows) while early apoptotic cells would exhibit a bright 
green-yellow due to chromatin condensation that occurs in early apoptosis (yellow arrows). 
Late apoptotic cells (blue arrows) would also have bright-red (or yellow-orange) nuclei 
with condensed or fragmented chromatin and necrotic cells would stain uniformly orange 
(red arrows). Magnification 100×. 
When treated with 4 µM (CaSki) and 6 µM (HeLa), there were both early apoptotic and some late 
apoptotic cells that stained red (blue arrows). At 24 h after treatment with the highest dose of 6 µM 
(CaSki) and 9 µM (HeLa), there was an increase in the number of early apoptotic cells, late apoptotic 
cells and necrotic cells (red arrows) which were bright orange in appearance in CaSki and HeLa cells 
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respectively. The gradual increase in early apoptotic cells (represented by yellow arrows) with 
increasing treatment concentration of MS17 was clearly demonstrated in Figures 5a and 6a. Forty eight 
hours after HeLa (Figure 5b) and CaSki (Figure 6b) cell treatment with 3 and 2 µM respectively, 
resulted in a mixed population of viable and early apoptotic cells. However in HeLa cells, there was 
also an observed appearance of late apoptotic cells when treated with 3 µM that was higher compared 
to CaSki cells treated with 2 µM. CaSki and HeLa cells treated with 4 µM and 6 µM respectively 
displayed increased early and late apoptotic cells and at the highest dose of 6 and 9 µM, there was a 
greater number of late apoptotic and necrotic HeLa and CaSki cells. 
2.2.2. Quantification of Apoptotic and Necrotic Cell Percentage 
In treated HeLa and CaSki cells (Figure 7), viable cells significantly decreased at 24 h in a  
dose-dependent manner from approximately 75% and 85% respectively to less than 10% and 5%. At 
48 h after treatment, there was a reduction in the viability of HeLa and CaSki cells from 65% and 85% 
respectively to less than 5% with increasing treatment dose. At 24 h after treatment with MS17, HeLa 
cells displayed an increase in early apoptotic cells at 3 µM (40%), 6 µM (60%) and 9 µM (50%). After 
48 h treatment, 50% of cells were maintained in early apoptosis induced by 3 µM but higher doses of 6 
and 9 µM exhibited a decrease (30% and 10% respectively) in early apoptosis. 
 
(a) 
Figure 6. Cont. 
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(b) 
Figure 6. (a) Detection by fluorescent microscopy of acridine orange/ethidium bromide 
double-stained control and MS17-treated CaSki cervical cancer cells (24 h). Viable cells 
have uniform green nuclei with organised structure (white arrows) while early apoptotic 
cells would exhibit a bright green-yellow due to chromatin condensation that occurs in 
early apoptosis (yellow arrows). Late apoptotic cells (blue arrows) would also have  
bright-red (or yellow-orange) nuclei with condensed or fragmented chromatin and necrotic 
cells would stain uniformly orange (red arrows). Magnification 100×; (b) Detection by 
fluorescent microscopy of acridine orange/ethidium bromide double-stained control and 
MS17-treated CaSki cervical cancer cells (48 h). Viable cells have uniform green nuclei 
with organised structure (white arrows) while early apoptotic cells would exhibit a bright 
green-yellow due to chromatin condensation that occurs in early apoptosis (yellow arrows). 
Late apoptotic cells (blue arrows) would also have bright-red (or yellow-orange) nuclei 
with condensed or fragmented chromatin and necrotic cells would stain uniformly orange 
(red arrows). Magnification 100×. 
The percentage of late apoptotic cells at 24 h was relatively low at all treatment doses (≤10%) but 
increased to approximately 40%–45% at 48 h. Necrotic cell percentage was maintained at 3 µM 
(approximately 10%) and 6 µM (approximately 25%) throughout the treatment period but increased at 
a dosing concentration of 9 µM to 40% and 50% at 24 and 48 h respectively. 
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Figure 7. Percentage of viable, apoptotic (early and late) and necrotic cells in (A) HeLa 
and (B) CaSki cells treated with MS17 for 24 and 48 h. Treated and non-treated cells were 
double stained and a minimum of 200 cells were counted per sample and the percentage of 
cells from each population (viable, live apoptotic, dead apoptotic, necrotic) was calculated. 
Experiments were performed in triplicates and results compared between two independent 
experiments. Results are expressed as means of percentage, with error bars depicting mean 
± SEM. Comparison between data sets were performed using ANOVA. Asterisks indicate 
statistically significant (* for p < 0.05, ** for p < 0.01, *** for p < 0.001, **** for  
p < 0.0001) differences between data sets for each treatment dose. 
Percentage of CaSki cells undergoing early apoptosis was relatively low at 24 h (10%) and 48 h 
(20%) when dosed at 2 µM but significantly increased to 85% at 24 h and 75% at 48 h as treatment 
dose increased to 4 µM. This was followed by a reduction in early apoptotic cells when treatment was 
increased to 6 µM at 24 h (55%) and 48 h (30%). Unlike HeLa cells, treated CaSki cells showed a 
relatively low percentage of late apoptotic cells (approximately ≤10%–15%) throughout the treatment 
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period. Treatment dose of 2 and 4 µM maintained a low percentage of necrotic cells (~10%) at 24 and 
48 h but showed a significant increase to 30% and 50% respectively when treated at 6 µM. 
In summary, MS17 appears to induce early apoptosis at 24 h after treatment of CaSki cells in a  
time- and dose-dependent manner. The percentage of necrotic cells at this time point is also relatively 
low. Results from the quantification of apoptotic and necrotic cells correspond to the cell morphology 
pattern observed in Figures 5 and 6. 
2.2.3. MS17 Increases Caspase-3 Activity 
The caspase-3 quantification assay (Figure 8) was performed to address whether treatment of the 
cervical cancer cells with MS17 causes increased caspase-3 activity. 
 
Figure 8. Relative caspase-3 activity in (A) HeLa and (B) CaSki cells treated with MS17 
at different time points. Experiments were performed in duplicates and results compared 
between two independent experiments. Results are expressed as the ratio of means of 
caspase-3 activity of treated samples over untreated samples and comparison between data 
sets performed using ANOVA. Asterisks indicate statistically significant (* for p < 0.05, 
*** for p < 0.001 and **** for p < 0.0001) differences between data sets for each 
treatment dose. Error bars depict mean ± SEM. 
CaSki cells showed low caspase-3 activity when treated with 2 μM and increased activity was noted 
at 48 h after treatment with 4 μM. However there was a significant threefold increase in relative 
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caspase-3 activity observed 24 h after treatment with 6 μM. In HeLa cells however, there were no 
significant differences observed in caspase-3 activity across all time points and doses upon MS17 
treatment. The data indicates that MS17 induces highest caspase-3 activity at 24 h following treatment 
with 6 μM in CaSki cells while there was no significant difference in treated HeLa cells between time 
points after treatment. 
2.2.4. MS17 Induces DNA Fragmentation 
A third validation assay was performed to assess whether exposure to MS17 caused cell death via 
apoptosis by studying the cytoplasm of treated cells for the presence of liberated oligonucleosomes due 
to DNA fragmentation caused by the treatment (Figure 9). 
 
Figure 9. Detection of nucleosomal enrichment in the cytoplasm of (A) HeLa and (B) 
CaSki cells treated with different concentrations of MS17 for 24, 48 and 72 h. Experiments 
were performed in duplicates and results compared between at least two independent 
experiments. Enrichment factor is expressed as mean ratio, with error bars depicting  
mean ± SEM. Comparison between data sets was performed using ANOVA. Asterisks 
indicate statistically significant (* for p < 0.05, ** for p < 0.01 and *** for p < 0.001) 
differences between the mean ratio of values obtained with treated vs. untreated cells. 
Increased cytoplasmic nucleosomal enrichment leads to enhanced enrichment factor, which denotes 
apoptotic activity. Treatment with 6 μM (HeLa) and 4 μM (CaSki) caused a significant 2.2- and 5-fold 
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increase in nucleosome enrichment in HeLa (p < 0.01) and CaSki (p < 0.001) respectively which 
peaked at 24 h after treatment but decreased thereafter. Treatment of HeLa cells with 6 μM at 48 h 
post-treatment also showed approximately two-fold increase in enrichment factor compared to the 
untreated cells (p < 0.05) but was significantly lower compared to enrichment at 24 h at the same 
treatment dose. There is no significant difference between doses at 48 h post-treatment for CaSki. At 
72 h post-treatment there is a significant reduction of enrichment factor in HeLa cells when treated 
with 6 and 9 μM but no significant reduction was noted for CaSki cells.The data indicates that MS17 
induces apoptosis in HeLa and CaSki by DNA fragmentation at 24 h after treatment. 
2.3. MS17 Down-Regulates E6 and E7 Viral Oncogene Expression 
Quantitative real-time polymerase chain reaction (RT-PCR) was used to study whether treatment 
with MS17 led to potential changes in oncogenic E6 and E7 mRNA expression in cervical cancer cells  
(Figure 10). 
 
Figure 10. E6 and E7 viral oncogene expression of treated (A) HeLa and (B) CaSki cells. 
At 24 h post-treatment with MS17, HPV18 E6/E7 and HPV16 E6/E7 mRNA levels in 
HeLa and CaSki cells were measured by quantitative real time PCR and normalized to  
β-actin mRNA levels. Expression is reported as mean fold-change in the level of mRNA in 
treated cells relative to control cells. Experiments were performed in duplicates and results 
compared between two independent experiments. Asterisks indicate statistically significant 
(** for p < 0.01, *** for p < 0.001 and **** for p < 0.0001) differences between the mean 
of values obtained with treated vs. untreated cells. Error bars depict mean ratio ± S.E.M. 
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Expression of HPV18 E6 and E7 viral oncogene reduced significantly between approximately 1.9- 
to 5.6-fold and 1.6- to 3-fold, respectively, compared to untreated HeLa cells. Most notable was that 
treated HeLa cells showed significantly greater reduction of E6 (p < 0.0001) and E7 (p < 0.001) 
expression at 9 μM. Treatment on CaSki cells also exhibited a dose-dependent decrease in oncogene 
expression; while treatment with 2 μM and 4 μM did not show significant inhibition of E6 and E7 
oncogene expression, treatment with 6 μM displayed a significant 3-fold decrease in HPV16E6 and 
HPV16E7 expression (p < 0.01) compared to untreated cells. Overall, treatment of HeLa cells with  
9 μM and CaSki cells with 6 μM respectively significantly reduced E6 and E7 viral oncogene 
expression in HeLa and CaSki cells. Hence, our data suggests that MS17 might be involved in the 
down regulation of HPV16 and HPV18 E6 and E7 oncogene expression. 
2.4. Discussion 
The present study aims to explore the potential anticancer activity of curcumin-like 
diarylpentanoids when treated on HPV-positive HeLa and CaSki human cervical cancer cells. 
Candidate compounds were shortlisted for in-depth study of their apoptotic capabilities by assessment 
of its cytotoxic potential compared to the parent compound, curcumin. 
Following treatment of HeLa and CaSki cells with four curcumin analogues, MS13, MS17, MS40E 
and MS49, it was observed that each compound exerted significant dose-dependent inhibition of cell 
viability that was improved over curcumin. There were however notable variations in terms of 
potency; MS17 showed the most cytotoxic effect on CaSki and HeLa cell viability corroborated by its 
relatively lower EC50 values, closely followed by MS13 which showed EC50 values which were 
approximately 2.5-fold higher. 
In previous investigations, Fajardo and colleagues established that curcumin analogue 27 (Ca27) 
which shares the same structure as MS17 caused significant cell death of C4-2 and LNCaP prostate 
cancer cells at concentrations of more than 2.5 μM and 10 μM respectively [30]. They concurred with 
several groups in assigning the potential cytotoxic capability of the analogue to its structure, 
specifically the α,β-unsaturated ketone, which acts as a Michael acceptor for nucleophilic groups [45]. 
FLLL-11, which is identical to MS13, was tested in breast and prostate cancer cells and reported 
IC50 values between 0.3 and 5.7 μM which were several fold lower than curcumin [46]. Hence the 
literature supports the cytotoxic effects of MS13 and MS17 in inducing cell death in prostate and 
breast cancer cell lines and to the best of our knowledge, ours is the first study comparing the effects of 
MS13 and MS17 in HeLa and CaSki cervical cancer cells. 
It was also observed that HeLa and CaSki demonstrated differing sensitivities to treatment with the 
diarylpentanoids (and curcumin); in each instance, treatment of CaSki consistently resulted in lower 
EC50 values compared to HeLa cells, and therefore suggests greater potency in CaSki compared to 
HeLa. Although both HeLa and CaSki are infected with high risk subtypes that cause cervical cancer, 
the cell lines originate from different sources. CaSki is a squamous cell carcinoma that makes up part 
of the epidermis while HeLa is an adenocarcinoma formed in epithelial glands. The derivation of 
CaSki and HeLa from different sources may explain the possible differences in their EC50 values in 
response to diarylpentanoid treatment. 
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Assessment of the SX values of diarylpentanoid treatment on cervical cancer cells revealed that 
MS13, MS17, MS40E and MS49 showed selective toxicity towards HeLa and CaSki over the  
non-tumoral cell line, MRC9. Of note is the fact that MS40E showed almost 4.5-fold higher SX in 
CaSki which may allude to the fact CaSki cells are particularly sensitive to the effects of MS40E.  
On average, it was observed that all diarylpentanoids displayed greater selectivity for toxicity in CaSki 
cells over HeLa. 
While the low EC50 values of diarylpentanoid treatment suggest a dose-dependent cytotoxic effect, 
treatment at 24, 48 and 72 h also indicated inhibition of cell proliferation rate in a time-dependent 
manner. Vehicle-treated control cells display proliferation over time while treatment appears to have a 
significant inhibitory impact on cell growth especially at later time points. 
Treatment of CaSki and HeLa cells from 12.5 and 25 μM respectively of MS40E and MS49, and 
treatment with 25 and 50 μM onwards of curcumin, caused a notable decline in cell viability at 24, 48 
and 72 h. However MS13 and MS17 exerted a substantial impact in anti-proliferative activity. 
Treatment with both diarylpentanoids induced significantly higher reduction in cell viability at 48 and 
72 h compared to 24 h but MS17 induced this effect at a dosage range that was two-fold lower (from 
6.3 and 3.1 μM respectively) compared to MS13 (from 12.5 and 6.3 μM respectively) in HeLa and 
CaSki cells. This suggests that the cytotoxic effects of the diarylpentanoids are largely influenced by 
dosage as well as treatment length. 
Apoptosis has been discussed as a common mechanism employed by cytotoxic agents [47,48] to 
induce cell death [49]; once initiated, the apoptotic process causes DNA fragmentation and 
morphologic changes which include blebbing, cell shrinkage, nuclear fragmentation and chromatin 
condensation [50]. Having established that MS17 induces time- and dose-dependent cytotoxic effects 
on HeLa and CaSki at relatively low EC50, a series of assays were employed to study whether key 
morphologic and biochemical hallmarks associated with apoptosis were present after treatment with 
MS17. In order to determine whether the effect of treatment was modulated by treatment dosage 
and/or time, cervical cancer cells were exposed to MS17 at approximate concentrations of its 
respective EC50, 2× EC50 and 3× EC50 at various time points. 
In the morphological discrimination of stained cells, it was observed that there was a heterogeneous 
cell population at each treatment dose, a typical property of cancer cells. Nonetheless, at specific 
doses, particular populations dominated over the others. It was noted that 24 h after HeLa and CaSki 
treatment with higher doses of MS17 resulted in a large proportion of early apoptotic cells compared 
to late apoptotic cells, denoted by bright green-yellow cells with chromatin condensation, which are 
classic features of apoptosis. A combination of high treatment dose and prolonged exposure, 
particularly with 6 µM (CaSki) and 9 µM (HeLa) for 48 h, led to the appearance of many bright orange 
cells as well, indicating that a proportion of the cells could be induced to undergo necrosis as a method 
of cell death, rather than apoptosis. These results are interesting as it denotes that a higher dosage for 
chemotherapy may not always be more effective; necrosis has many adverse cellular consequences 
while apoptosis causes little tissue disruption and no inflammation [50]. This could be one of the many 
reasons apoptosis has been heralded as a more efficient strategy for chemotherapy rather than necrosis. 
Hence, morphological assessment of treated HeLa and CaSki cells suggests that MS17 has the 
capability of inducing early apoptosis in a time- and dose-specific manner. 
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In the induction of programmed cell death, many key factors play crucial roles in mediating 
apoptotic response. Caspases are a family of proteinases that are constitutively present as zymogens 
within the cell; when cleaved, its activation in turn initiates a cascade of proteolytic cleavage of 
caspases. Activation of the key downstream executor, caspase-3, results in the morphological 
characteristics associated with apoptosis and eventually leads to DNA degradation [51]. It is therefore 
notable that in the present work, caspase-3 activity was noted to be highest at 24 h following treatment 
with 6 µM in CaSki cells. Treatment with MS17 also induces a peak in nucleosome enrichment due to 
DNA fragmentation observed at 24 h in CaSki (4 µM) and HeLa (6 µM) cells. However, there were no 
observable significant differences of caspase-3 activity in treated HeLa cells. This was interesting to us 
as MS17-treated HeLa cells were showing features of apoptotic activation in morphological 
assessment and DNA fragmentation and suggests that the mechanism of apoptosis induced in HeLa 
cells by MS17 may be caspase-3 independent. While HeLa typically undergoes caspase-dependent 
apoptosis, previous literature has shown that depending on the compound it is exposed to, HeLa cells 
have been shown to induce a caspase-independent apoptotic process [52]. 
The cytotoxic and apoptotic effects of MS17 treatment were accompanied by decrease of E6 and E7 
viral oncogene expression in HeLa and CaSki cells across doses but displayed a highly significant 
downregulation at 9 and 6 μM respectively, proposing that MS17 may also be involved in interfering 
or associating with the cellular processes that regulate viral gene expression. This could have 
significant implications as E6 and E7 are crucial oncoproteins due to its interaction with tumor 
suppressor proteins p53 [53] and retinoblastoma (Rb) [54] respectively. Interestingly, E6 and E7 can 
immortalize cells independently but when present together, shows a synergistic effect that has marked 
efficiency in transforming activity [55]. Studies have shown that mutations in the E6 or E7 open 
reading frame completely abolished the tumorigenicity of cervical cancer cells suggesting that both E6 
and E7 oncogenes are necessary for the malignant phenotype of HPV-positive cervical cancer  
cells [56,57]. E7 interacts with and degrades Rb and releases transcription factor E2F from Rb 
inhibition, thus stimulating cyclin genes [58], inactivate their inhibitors [59–61] and contributes to 
tumorigenesis. The efficient binding of Rb by E7 would typically lead to inhibited cell growth and 
induce apoptosis through a p53-dependent pathway in E7-expressing cells. Thus E6 has evolved to 
cause degradation of p53; as a consequence, p21 protein is not made available as a “stop” signal for 
cell division thus resulting in genomic instability. Furthermore, the pro-apoptotic protein, Bak, is also 
degraded causing resistance to apoptosis [62]. 
The results reported here correspond with studies where curcumin treatment of cervical cancer cells 
inhibits transcription of E6 and E7 oncogenes and restores the expression of tumour suppressor 
proteins p53 and retinoblastoma [11]. Singh et al., have demonstrated [63] that curcumin is able to 
induce apoptosis and E7 oncoprotein down-regulation in HPV-positive cervical cancer cells. Significant 
decline in the expression levels of E6 and E7 proteins in SiHa HPV16-positive cells treated with 
curcumin for 24 h [64] was noted and they concluded that loss of E6/E7 culminates in apoptotic cell 
death in these cervical cancer cells. Hence, down-regulation of key oncogenes in this study could be 
contributing to the sensitivity of the cervical cancer cells to apoptotic cell death when treated  
with MS17. 
Overall, the present study demonstrates that treatment with four curcumin diarylpentanoids, MS13, 
MS17, MS40E and MS49, had comparably improved cell viability inhibition of HPV-positive human 
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cervical cancer cells compared to the parent compound, curcumin. Anti-proliferative studies indicate 
that MS17 treatment caused significant inhibition of cell proliferation at 48 and 72 h of treatment, 
compared to 24 h. The potential candidate MS17 was chosen based on cytotoxic and anti-proliferative 
data and a series of downstream apoptotic assays suggest that MS17 induces DNA fragmentation and 
classical morphological features of apoptosis such as chromatin condensation in HeLa and CaSki cells 
as well as activation of caspase-3 activity in CaSki cells. MS17 also causes downregulation of crucial 
HPV oncogenes that are responsible for progression of cervical carcinoma which may also result in 
cell death. Future treatments of cervical cancer may also include the exploration of combinatorial 
strategies of MS17 with chemotherapeutic drugs that are currently in use. On its own, curcumin has 
shown strong cytotoxicity on Hodgkin’s Lymphoma (HL) cells but when used in combination with 
cisplatin, a more potent toxic effect was noted. It was hypothesized that curcumin may be involved in 
cisplatin sensitization in HL cells and the synergistic effects of curcuminoids [65], including MS17 
with other drugs, presents an intriguing avenue for future investigation. 
To the best of our knowledge, the data in this study is a novel report describing the cytotoxic,  
anti-proliferative and apoptotic effects of the diarylpentanoid MS17 in HeLa and CaSki cervical cancer 
cells. Nonetheless, these initial findings warrant further investigation to fully elucidate the molecular 
pathways involved in the mechanism of its action as well as the assessment of its effects using  
in vivo models. 
3. Experimental Section 
3.1. Cell Culture 
HPV-infected human cervical cancer cell lines, HeLa and CaSki, and human fetal lung fibroblasts, 
MRC-9, were obtained from American Type Culture Collection (ATCC, Rockville, MD, USA) and 
maintained using appropriate media. HeLa and MRC-9 were maintained using MEM medium (Gibco, 
Grand Island, NY, USA), and RPMI 1640 (Gibco) was used to maintain CaSki cells. All cell lines 
were maintained with respective media supplemented with 10% Fetal Bovine Serum (FBS, Gibco) and 
penicillin (100 U/mL)/streptomycin (100 µg/mL) (Gibco). These cells were cultured at 37 °C in a 
humidified atmosphere with 5% CO2. HeLa and CaSki cells are reported to contain HPV type 18 and 
16 (high-risk) viral genome sequences respectively. 
3.2. Preparation of Curcumin Analogues 
Four chemically synthesized and purified diarylpentanoids [41], namely 1,5-bis(4-hydroxy-3-
methoxyphenyl)-1,4-pentadiene-3-one (MS13), 1,5-bis(2-hydroxyphenyl)-1,4-pentadiene-3-one (MS17), 
1,5-bis(3-fluorophenyl)-1,4-pentadiene-3-one (MS40E) and 2,6-bis(3-fluorobenzylidene)cyclohexanone 
(MS49) were prepared by coupling the appropriate aromatic aldehyde with acetone, cyclopentanone 
and cyclohexanone under base catalyzed aldol condensation, using a ketone-aldehyde ratio of 1:2 [66]. 
All compounds were characterized based on analysis of their spectroscopic data and comparison of 
these data with those of related compounds. Curcumin was obtained from commercial sources (Sigma 
Aldrich, St. Louis, MA, USA). 50 mM concentrations of diarylpentanoid stock solutions were prepared 
in DMSO (Sigma Aldrich). 
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3.3. Cell Viability and Anti-Proliferative Assays 
HeLa, CaSki and MRC9 cells were plated in triplicate wells in 96-well flat-bottomed tissue culture 
plates (Nunc, Roskilde, Denmark) with 105 cells per mL in 100 μL culture media with working 
concentrations of diarylpentanoid treatment ranging from 1.6 to 100 μM. Control-treated wells 
contained cells incubated in media with equal volumes of DMSO (0.2%). Cells were treated for 72 h for 
dose-dependent cytotoxicity assays and at 24, 48 and 72 h for anti-proliferative (time-dependent) 
assays. In order to assess cell viability and anti-proliferative activity after diarylpentanoid treatment, 
the colorimetric 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay was 
performed as previously described with modifications [67]. The media was aspirated and cells were 
incubated in 100 µL complete medium with 0.5 mg/mL MTT solution for 4 h in the dark to allow 
metabolism of MTT by cellular mitochondrial dehydrogenases. The excess MTT was aspirated and the 
formazan crystals formed were dissolved by the addition of 100 µL of DMSO. The absorbance of dark 
blue formazan was read at 570/650 nm wavelengths using a microplate reader (Bio-Rad Benchmark Plus 
Microplate Spectrophotometer, Hercules, CA, USA). Triplicate absorbance values were averaged and 
the effect of the compounds on growth inhibition was assessed as percentage cell viability as follows: 
Percentage cell viability =
Absorbance of Test −  Absorbance of Blank (media only)
Absorbance of Control −  Absorbance of Blank (media only) 	× 100 (1)
where, absorbance = optical density of sample, O.D.; control = untreated sample; test = treated sample. 
An independent set of vehicle-treated (DMSO only) controls were included in the anti-proliferative 
assays to assess the proliferation of untreated cancer cells over 24, 48 and 72 h. As such, the cell 
viability at 24 h was used as a baseline to measure proliferation rate at 48 and 72 h. 
Percentage cell viability = 
Absorbance of Control (Time) × Absorbance of Blank (media only)
Absorbance of Control (24 h) × Absorbance of Blank (media only)
 × 100 (2)
The results were analysed using GraphPad Prism version 6.00 for Windows (GraphPad Software, 
La Jolla, CA, USA). Using percentage cell viability Equation (1), log dose–response curves were 
constructed, from which the half maximal effective concentration, EC50 for each replicate was 
determined. Overall EC50 was determined by taking the average EC50 from three independent 
experiments. Using the EC50 values of the compounds obtained from cytotoxicity assays in HeLa, 
CaSki and MRC9 cells lines, the selectivity index (SX) values of the diarylpentanoids were calculated 
according to the equation below as previously established [42]. 
Selectivity Index (SX) =
ECହ଴ (MRC9)
ECହ଴ (Cancer cell line)
 × 100 (3)
SX is used to determine whether a selected compound possesses greater selectivity for achieving 
therapeutic effects in cancerous cells while producing minimal toxicity on normal cells. Similar to 
previous practice [42,68], “100” was determined as the baseline; compounds that showed a SX value 
more than 100 would indicate a dosing concentration that selectively achieves higher therapeutic 
potential for cancerous cells over causing toxicity in non-cancerous cells; these compounds would 
ideally be chosen for further development. Selected diarylpentanoids were further studied in apoptotic 
induction assays. 
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3.4. Induction of Apoptosis with Selected Diarylpentanoids 
For apoptotic assays, cancer cells were exposed to MS17 at approximate concentrations of its 
respective EC50 [CaSki, 2 μM; HeLa, 3 μM], 2× EC50 [CaSki, 4 μM; HeLa, 6 μM] and 3× EC50 
[CaSki, 6 μM; HeLa, 9 μM] at various time points. Each experiment included a set of untreated control 
cells (Media with DMSO alone). 
3.4.1. Acridine Orange-Ethidium Bromide Staining for Morphological Evaluation of Apoptosis 
Double staining with acridine orange and ethidium bromide and consequently fluorescent microscopic 
analysis is an established method by which to distinguish between viable, necrotic and apoptotic  
cells [43,44]. HeLa and CaSki cervical cancer cells were exposed to MS17 for 24 and 48 h at 
concentrations of their respective EC50, 2× EC50 and 3× EC50. Following treatment, the cells were 
pelleted, washed twice in 1× PBS and resuspended in 50 μL 1× PBS. 1 μL of dye mixture (1 part  
100 μg/mL acridine orange in PBS and 1 part 100 μg/mL ethidium bromide in PBS) was added to  
10 μL of cell suspension and the entire volume was placed on a clean microscope slide. Cells were 
examined by fluorescence microscopy using the fluorescein filter (BX41, Olympus, Melville, NY, 
USA) and were distinguished via the morphological aspect of chromatin condensation in stained nuclei 
as previously established [69]. A minimum of 200 cells were counted per sample and the percentage of 
cells from each population (viable, live apoptotic, dead apoptotic, necrotic) was calculated. 
3.4.2. Quantification of Relative Caspase-3 Activity 
Caspase-3 activity was assessed using the Caspase-3 Colorimetric Assay Kit (Sigma Aldrich), 
following the manufacturer’s instructions. Briefly, 4 × 105 cervical cancer cells were plated in 6-well 
tissue culture plates, left to attach for 24 h before being exposed to MS17 at concentrations of its 
respective EC50, 2× EC50 and 3× EC50 for 12, 24, 48 and 72 h. Following treatment, the cells were 
washed in PBS and suspended in a lysis buffer (50 mM HEPES pH 7.4, 5 mM CHAPS, 5 mM DTT) 
for 25 min at a concentration of 107 cells per 100 μL of buffer. Lysed cells were centrifuged at  
16,000× g, 4 °C for 30 min. Lysate protein concentration was determined using the Cayman Chemical 
Protein Determination (Cayman Chemical Company, Ann Arbor, MI, USA) kit which is a colorimetric 
method for total protein quantification based on the Bradford method. In short, 100 μL of protein 
samples was diluted in 96-well plates and 100 μL of the assay reagent was added to the samples, 
incubated for 5 min and the absorbance measured at 595 nm. Protein concentrations were calculated 
from a regression line fit to a series of standard protein dilutions assays on the same plate as the 
unknown samples. Approximately 100 μg total protein from each sample were added to wells 
containing the assay buffer (20 mM HEPES, pH 7.4, 0.1% CHAPS, 5 mM DTT, 2 mM EDTA), followed 
by 10 μL of Ac-DEVD-pNA (20 mM), bringing the total volume of each well to 100 μL. The effect of 
Ac-DEVD-CHO, a caspase-3 inhibitor, on caspase-3 activity was studied simultaneously. As per the 
manufacturer’s instructions, 10 μL of the inhibitor Ac-DEVD-CHO (200 μM) was added to a well 
containing the assay buffer, followed immediately by the cell lysate and 10 μL of the substrate  
Ac-DEVD-pNA (2 mM). Caspase-3 activity was assessed by measuring the absorbance released by the 
pNA molecule at 405 nm using a Bio-Rad Benchmark Plus Microplate Spectrophotometer. Caspase-3 
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activity was expressed by measuring the ratio of the mean caspase-3 activity of treated cells relative to 
untreated cells. 
3.4.3. DNA Fragmentation by Immunochemical Detection of Histone-Complexed Mono-  
and Oligonucleosomes 
The enrichment of the cytoplasm of treated cells by mono- and oligonucleosomes are used to study 
whether enhanced DNA fragmentation is induced by diarylpentanoid treatment. This determination 
was made following the manufacturer’s instructions of the Cell Death Detection ELISAPLUS kit (Roche 
Diagnostics, Mannheim, Germany). Briefly, HeLa and CaSki cervical cancer cells were exposed to 
MS17 for 24 and 48 h at concentrations of their respective EC50, 2× EC50 and 3× EC50. Following 
treatment, the cells were incubated in lysis buffer and centrifuged, after which the supernatant was 
transferred to streptavidin coated plates and shaken with the provided immunoreagent (mixture of  
anti-DNA-POD and anti-histone biotin) for 2 h. This incubation period was followed by thorough 
rinsing with incubation buffer to remove unbound antibody and processed for colour development by 
addition of the chromogenic substrate for the peroxidase containing 2,2′-azino-di-[3-ethylbenzthiazoline 
sulfonate (ABTS) and photometric analysis at 405/490 reference wavelengths. Enrichment factor,  
defined as the release of mono- and oligonucleosomes into the cytoplasm, was calculated using the 
formula below: 
Enrichment factor =
Absorbance of Test −  Absorbance of Blank (substrate only)
Absorbance of Control − Absorbance of Blank (substrate only) (4)
3.5. Quantitative Reverse-Transcription Polymerase Chain Reaction (RT-PCR) for Viral Oncogenes 
E6 and E7 
RNA extraction was performed using the Qiagen RNeasy® Mini Kit (Qiagen, Valencia, CA, USA). 
According to the manufacturer’s instructions, treated HeLa and CaSki cells were lysed using Buffer 
RLT (supplemented with β-mercaptoethanol) and centrifuged for 3 min at maximum speed. 70% 
ethanol was added to the lysate and placed in an RNeasy Mini spin column and spun at ≥8000× g for 
15 s. Flow-through was discarded and the pellet was subjected to a series of wash steps using buffers 
RW1 and RPE and subsequent RNA elution. On-column RNase-Free DNase (Qiagen) treatment was 
incorporated into the extraction protocol to eliminate DNase contamination of genomic DNA. 
Concentration and purity of extracted RNA was measured spectrophotometrically using NanoDrop 
1000 (Thermo Fisher Scientific, Wilmington, DE, USA). Two μg of total RNA per 20 μL reaction was 
used for complementary DNA (cDNA) synthesis using a High Capacity RNA-to-cDNA kit (Applied 
Biosystems, Life Technologies, Foster City, CA, USA). Appropriate volumes of RNA sample were 
added to 10 μL 2XRT Buffer and 1 μL 20X RT Enzyme Mix and the total volume was adjusted to  
20 μL using nuclease-free water. Reverse transcription was performed on the samples using the 
following conditions; 37 °C for 60 min and 95 °C for 5 min. The sequences used to design the primers 
and TaqMan® probes were obtained from previous publications [70,71], synthesized by Applied 
Biosystems and optimized to amplify the HPV16 and HPV18 E6 and E7 regions (sequences listed in 
Table 2) using the StepOnePlus™ Real-Time PCR system (Applied Biosystems). The optimized 
concentrations of the primers and probes used were 900 nm and 250 nm respectively. Human  
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VIC®-MGB ACTB (β-actin) was used as an endogenous control for internal normalisation and relative 
gene expression quantification. Each reaction was run in duplicates and used to calculate relative gene 
expression using the 2−∆∆CT method. Expression is reported as fold change in the level of mRNA of 
treated cells relative to untreated cells, normalised to β-actin expression. 
Table 2. Primer and probe sequences used in quantitative TaqMan® real-time PCR assays 
measuring the specific viral oncogene expression after MS17 treatment. 
Target Forward Primer Reverse Primer Fluorescent Hybridisation Probe a 
HPV 16E6 
CTGCGACGTGAGGTATATG
ACTTT 
ACATACAGCATATG
GATTCCCATCT 
6FAM-CTTTTCGGGATTTATGC-
MGB-NFQ [71] 
HPV 16E7 
CAAGTGTGACTCTACGCTTC
GG 
GTGGCCCATTAACA
GGTCTTCCAA 
6FAM-
TGCGTACAAAGCACACACGTAGAC
ATTCGT-TAMRA [71] 
HPV 18E6 
CTATAGAGGCCAGTGCCATT
CG 
TTATACTTGTGTTTC
TCTGCGTCG 
6FAM-
CAACCGAGCACGACAGGAACGACT
CCA-TAMRA [70] 
HPV 18E7 
TAATCATCAACATTTACCAG
CCCG 
CGTCTGCTGAGCTTT
CTACTACTA 
6FAM-
CGAGCCGAACCACAACGTCACACA
ATGTT-TAMRA [70] 
a FAM™ was used as the reporter dye in all probes; TAMRA™ and MGB-NFQ were used as quencher dyes 
depending on probe sequence length. 
3.6. Statistical Analysis 
Results were presented as means ± S.E. All samples were measured in triplicates (unless stated 
otherwise) for each independent experiment. Comparison between datasets was performed using  
two-way analysis of variance (ANOVA) followed by Dunnet’s multiple group comparison test. 
Statistical significance between groups was accepted at p < 0.05. All statistical analyses were 
performed using GraphPad Prism version 6.00 for Windows, GraphPad Software (San Diego, CA, USA). 
4. Conclusions 
In conclusion, 1,5-bis(2-hydroxyphenyl)-1,4-pentadiene-3-one (MS17) was shown to have 
significant cytotoxic effects on HeLa and CaSki cervical cancer cells, denoted by its relatively low 
EC50 value and its significant anti-proliferative effects at 48 and 72 hours of treatment compared to the 
other curcumin analogues tested here. Its apoptosis-inducing ability and down-regulation of HPV-positive 
oncogenes make it a prospective option for further investigation into its chemotherapeutic potential for 
cervical cancer treatment. 
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